Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H; Japan Study Group of Prostate Cancer (J-CaP). Hinotsu S, et al. Among authors: namiki m. Jpn J Clin Oncol. 2007 Oct;37(10):775-81. doi: 10.1093/jjco/hym098. Epub 2007 Oct 26. Jpn J Clin Oncol. 2007. PMID: 17965423
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M, Ohashi Y. Arai Y, et al. Among authors: namiki m. J Cancer Res Clin Oncol. 2008 Dec;134(12):1385-96. doi: 10.1007/s00432-008-0409-z. Epub 2008 May 20. J Cancer Res Clin Oncol. 2008. PMID: 18491137 Clinical Trial.
Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
Kitagawa Y, Ueno S, Izumi K, Mizokami A, Hinotsu S, Akaza H, Namiki M. Kitagawa Y, et al. Among authors: namiki m. J Cancer Res Clin Oncol. 2014 Apr;140(4):673-9. doi: 10.1007/s00432-014-1612-8. Epub 2014 Feb 13. J Cancer Res Clin Oncol. 2014. PMID: 24522405
Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.
Inamoto T, Azuma H, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Kazuhiro S, Naito S, Namiki M, Nishimura K, Hirao Y, Usami M, Murai M, Akaza H; Japan Study Group of Prostate Cancer (J-CaP). Inamoto T, et al. Among authors: namiki m. J Cancer Res Clin Oncol. 2014 Jul;140(7):1197-204. doi: 10.1007/s00432-014-1638-y. Epub 2014 Mar 28. J Cancer Res Clin Oncol. 2014. PMID: 24676427
Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Tsukamoto T. Onozawa M, et al. Among authors: namiki m. Cancer Med. 2018 Oct;7(10):4893-4902. doi: 10.1002/cam4.1735. Epub 2018 Aug 27. Cancer Med. 2018. PMID: 30151999 Free PMC article.
839 results